GS
NAMSW icon

GTS Securities’s NewAmsterdam Pharma Warrant NAMSW Stock Holding History

GTS Securities’s Portfolio NAMSW Stock Details NAMSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-121,150
Closed -$1.34M – 4191
2024
Q1 		$1.34M Buy
+121,150
New +$1.1M ﹤0.01% 1767

Other funds holding NAMSW

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $812M AUM 17.34% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

GTS Securities's NAMSW Position: Q2 2024 in Review

GTS Securities sold out of NewAmsterdam Pharma Warrant (NAMSW) in Q2 2024, closing a stake of 121,150 shares — an estimated $1.34M sold.

GTS Securities first reported a position in NAMSW in Q1 2024 and held it in 1 quarter. The position peaked at $1.34M in Q1 2024. 10 funds tracked by Wall St. Rank hold NAMSW as of Q2 2024.

  • GTS Securities reported no remaining NewAmsterdam Pharma Warrant position as of Q2 2024 after selling out during the quarter.
  • GTS Securities sold 121,150 NewAmsterdam Pharma Warrant shares in Q2 2024, an estimated $1.34M.
  • GTS Securities first reported a position in NewAmsterdam Pharma Warrant in Q1 2024 and held it in 1 quarter.
  • GTS Securities's NewAmsterdam Pharma Warrant position peaked at $1.34M in Q1 2024.
  • 10 funds tracked by Wall St. Rank held NewAmsterdam Pharma Warrant as of Q2 2024.

Based on GTS Securities's 13F filing for Q2 2024, filed 14 Aug 2024.